BridgeMD
New treatment option for Alzheimer Disease
Official title Olfactory Biopsies
ClinicalTrials.gov ID: NCT07021040
What this study is testing
- What it's testing
- This research study aims to investigate the function of the olfactory lining in the nasal cavity and its potential alterations in both healthy and diseased conditions. The olfactory lining is involved in the sense of smell.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Group 1: Alzheimer's study
- Between the ages of 18 and 80
- Pre-clinical AD (this cohort consists of people who have normal cognitive testing and function, but have positive AD biomarkers);
- Symptomatic AD (a confirmed diagnosis of Alzheimer's or dementia who are capable of understanding and signing the consent document)
You likely can't join if
- Advanced Alzheimer's/dementia
- Self-reported or known allergy to Afrin or Tetracain HCL (or related class of drugs)
- Active Rhinosinusitis symptoms
- Other known sinonasal disease history that would preclude biopsy (i.e prior sinus or skull base surgery directly impacting this anatomic region...
- Parkinson's disease
- Unable or willing to complete the nasal endoscopy procedure.
See the full eligibility criteria
- Group 1: Alzheimer's study
- Between the ages of 18 and 80
- Pre-clinical AD (this cohort consists of people who have normal cognitive testing and function, but have positive AD biomarkers);
- Symptomatic AD (a confirmed diagnosis of Alzheimer's or dementia who are capable of understanding and signing the consent document)
- Advanced Alzheimer's/dementia
- Self-reported or known allergy to Afrin or Tetracain HCL (or related class of drugs)
- Active Rhinosinusitis symptoms
- Other known sinonasal disease history that would preclude biopsy (i.e prior sinus or skull base surgery directly impacting this anatomic region, sinonasal neoplasm in this anatomic region, olfactory cleft polyps)
- Parkinson's disease
- Unable or willing to complete the nasal endoscopy procedure.
- Unable to read or speak English
- Unable to provide legally effective consent Group 2: Act-seq study or Non-AD controls Inclusion Criteria:
- Age 18 years or older
- Patients being seen for rhinology or olfactory disorders
- Patients having unrelated endoscopic nasal surgery Exclusion Criteria:
- Self-reported or known allergy to Afrin or Tetracain HCL (or related class of drugs)
- Unable or willing to complete the nasal endoscopy procedure
- Unable to read or speak English
- Unable to provide legally effective consent
The study team makes the final eligibility decision.
Where it's taking place
- Durham, North Carolina, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Durham, North Carolina, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.